THE CHROMOSOME | Clinical Content Series
Type 2 Diabetes
Back to Case Studies ArchiveCase Study
She was 46 years old and had been diabetic for six years. She was on three medications. Her HbA1c, the three month blood sugar average that Pakistani physicians use as the primary measure of diabetic control, had never come below 8.2 percent despite every medication adjustment her physician had attempted. She had been told she was non compliant. She had been told she was not following her diet. She had been told, with increasing impatience by a physician who had run out of pharmaceutical options, that she needed to try harder.
She was trying as hard as a human being can try. The problem was not her effort. The problem was that her diabetes had never been understood correctly, and therefore had never been treated correctly.
When she arrived at my clinic she was carrying 31 kilograms of excess weight, predominantly visceral, with the distribution pattern I have come to recognise immediately in Pakistani women with long standing insulin resistant type 2 diabetes. Her fatigue was profound. Her feet were beginning to show the early signs of peripheral neuropathy, the tingling and numbness that signals diabetic nerve damage already in progress. Her kidney function tests showed early microalbuminuria. Her retinal examination revealed the first signs of diabetic retinopathy. Six years of inadequate metabolic control had already begun to extract its biological price.
Her HbA1c told one story. Her fasting insulin told another, and it was the more important one. Her insulin was still being produced in significant quantities. This was not a pancreas that had failed. This was a pancreas working desperately hard against an insulin resistance so severe that even maximal pharmaceutical support could not overcome it. Her cells were refusing the insulin signal with such consistency that no amount of medication could force sufficient glucose uptake to bring her blood sugar under control.
This is the central misunderstanding of type 2 diabetes management in Pakistani medicine. HbA1c is treated as the target. Insulin resistance, the biological condition producing the elevated HbA1c, is almost never directly addressed. Medications are added to force blood sugar down while the underlying metabolic failure that is driving it up continues to worsen. The patient takes more medication, achieves partial control, and deteriorates toward complications while their physician measures success in HbA1c points rather than in biological restoration.
The FTO gene's relationship with type 2 diabetes in Pakistani patients is among the most extensively documented in Pakistani medical research. Studies from Lahore, Karachi, and across the Pakistani diabetic population confirm that the FTO variant significantly increases type 2 diabetes risk in Pakistanis, not merely through its effect on body weight but through its direct influence on pancreatic beta cell function, insulin sensitivity, and the inflammatory pathways that accelerate beta cell exhaustion. Pakistani patients develop type 2 diabetes at lower body weight thresholds, at younger ages, and with more rapid progression to complications than Western populations at equivalent metabolic burden, and this is a genetically influenced biological reality that Pakistani diabetes management has never adequately incorporated into its clinical approach.
I did not add a fourth medication. I treated the insulin resistance that was making three medications insufficient. I reduced her visceral fat, the inflammatory engine suppressing her insulin signalling. I recalibrated her cortisol, which had been driving hepatic glucose overproduction overnight. I addressed her thyroid conversion impairment, which had been slowing her metabolic rate and deepening her glucose handling deficit. I deployed peptide based interventions targeted at pancreatic beta cell recovery and insulin sensitivity restoration.
Fourteen months later her HbA1c was 6.1 percent, within the normal range, on one medication rather than three. Her microalbuminuria had resolved. Her neuropathy symptoms had improved significantly. She had lost 24 kilograms.
She had not needed to try harder. She had needed a physician who understood that her diabetes was a metabolic disease with a biological solution, not a compliance problem with a pharmaceutical one.
FAQs
Pakistani patients develop type 2 diabetes at significantly lower body weight thresholds, younger ages, and with more rapid progression to complications than Western populations, and this is not simply a lifestyle difference. The FTO gene variant prevalent in the Pakistani population directly impairs pancreatic beta cell function and insulin sensitivity, reducing the metabolic reserve available before clinical diabetes emerges. Pakistani patients have less biological buffer between insulin resistance and overt diabetes than Western patients at equivalent degrees of obesity. Research across Pakistani diabetic populations confirms this genetic amplification of diabetes risk, establishing it as a population specific biological reality that demands earlier intervention, more comprehensive assessment, and more aggressive metabolic treatment than Pakistani clinical guidelines currently provide.
Managing blood sugar means using medication to keep glucose levels within an acceptable range while the underlying biological condition, insulin resistance and progressive beta cell exhaustion, continues to worsen. Treating type 2 diabetes means addressing the metabolic drivers that are producing the elevated blood sugar in the first place. The distinction matters profoundly because a patient whose blood sugar is medically controlled but whose insulin resistance is worsening is still progressing toward complications, kidney disease, neuropathy, retinopathy, cardiovascular disease, because these complications are driven by the metabolic environment, not merely by the glucose number. Dr. Zaar treats the metabolic environment, using HbA1c as a progress marker rather than as the therapeutic target itself.
The FTO gene at Chromosome 16q12.2 influences type 2 diabetes risk in Pakistani patients through multiple simultaneous pathways. It impairs hypothalamic regulation of insulin secretion timing and amplitude. It reduces peripheral insulin sensitivity through its effects on adipose tissue distribution and inflammatory signalling. It promotes visceral fat accumulation, which drives the inflammatory cytokine release that directly damages pancreatic beta cells over time. And it alters the hepatic glucose production rhythm in ways that produce elevated fasting blood glucose even before peripheral insulin resistance becomes severe. Research from Pakistani institutions confirms significant FTO variant association with type 2 diabetes in Pakistani cohorts, establishing a genetic predisposition that clinical management must account for rather than ignore.
Visceral fat releases inflammatory cytokines directly into the portal circulation, bathing the liver, pancreas, and kidneys in a continuous inflammatory environment that accelerates the vascular and cellular damage underlying diabetic complications. In the kidney, visceral fat derived inflammation promotes glomerular damage and microalbuminuria, the earliest sign of diabetic nephropathy. In the vasculature, it promotes endothelial dysfunction and atherosclerosis, the substrate for diabetic cardiovascular disease. In the pancreas, it drives ongoing beta cell exhaustion through direct cytotoxic inflammation. Pakistani patients with significant visceral fat accumulation progress toward diabetic complications faster than their HbA1c alone would predict, because the inflammatory load driving complications operates independently of blood glucose control.
Type 2 diabetes is reversible in Pakistani patients who retain meaningful pancreatic beta cell function, which is the majority of patients in the earlier stages of the condition. Reversal requires achieving sufficient visceral fat reduction to remove the inflammatory suppression of insulin signalling, restoring insulin sensitivity to the point where pancreatic output can maintain normal glucose levels without pharmaceutical support, and recalibrating the entire hormonal environment that has been perpetuating the diabetic state. Dr. Zaar has achieved complete diabetic remission, normal HbA1c without diabetes medication, in a significant proportion of patients treated comprehensively through THE CHROMOSOME protocol. Reversal is not guaranteed and is not appropriate as a promise, but it is a biologically achievable outcome that Pakistani diabetes management almost never pursues because it requires treating the whole metabolic system rather than the glucose number.
Cortisol is a glucose raising hormone, it stimulates hepatic glucose production and reduces peripheral insulin sensitivity as part of its stress response function. In Pakistani patients with cortisol dysregulation, this glucose raising effect operates continuously rather than transiently, particularly overnight, when dysregulated cortisol drives hepatic glucose overproduction that produces the elevated fasting blood glucose that is among the most difficult aspects of Pakistani type 2 diabetes to control pharmaceutically. The dawn phenomenon, the early morning blood glucose rise that confounds Pakistani diabetic management, is in many patients a cortisol phenomenon rather than a purely diabetic one. Treating the cortisol pattern resolves the dawn phenomenon more effectively than adding medication, but cortisol is almost never assessed in Pakistani diabetic patients.
The gut microbiome, the community of bacteria inhabiting the digestive tract, plays a significant and increasingly recognised role in insulin sensitivity, glucose metabolism, and systemic inflammation. In Pakistani patients, the combination of antibiotic overuse, refined carbohydrate dietary patterns, chronic stress, and the inflammatory consequences of visceral obesity creates a gut microbiome environment characterised by reduced bacterial diversity and increased populations of inflammation promoting species. This dysbiotic gut environment contributes to systemic inflammation, worsens insulin resistance through lipopolysaccharide mediated immune activation, impairs the gut hormone responses that regulate postprandial glucose, and promotes the visceral fat accumulation that drives diabetic progression. THE CHROMOSOME protocol incorporates gut health assessment and recalibration as a component of comprehensive diabetic management, because the gut is a metabolic organ whose dysfunction contributes to diabetic pathophysiology in ways that no diabetes medication addresses.
Because medications control the glucose number without restoring the biological health of the metabolic system producing the abnormal number. Metformin reduces hepatic glucose production. Sulphonylureas force the pancreas to produce more insulin. SGLT2 inhibitors cause glucose to be excreted in urine. Each intervention addresses a mechanism without addressing the underlying insulin resistance, visceral inflammation, hormonal dysregulation, and pancreatic exhaustion that are driving the diabetic process forward. The complications of diabetes, kidney disease, neuropathy, retinopathy, cardiovascular disease, are driven by the metabolic environment as much as by the glucose level. A Pakistani diabetic patient with controlled HbA1c but persistent visceral obesity, insulin resistance, and systemic inflammation is still progressing toward complications. THE CHROMOSOME protocol treats the environment, which is where complications are born and where they must be prevented.